Category Archives: Industry News

INSIDE THIS ISSUE Code Updates: Large Price Changes Reminder – NEW HCPCS Q-Codes effective July 1, 2018  CMS NEWS: April 1, 2018 NOC Pricing File Updated Drug Reimbursement Code Price Updates  Drugs/Devices: New Clinical and Billing Information New Webinar: Shedding Light on Medically Covered Specialty Drug Pricing Methods Let’s discuss Specialty Drug Pricing Methods… WAC. […]

May 2018 Specialty Drug FDA Actions In May there were a total of five new drug approvals by the FDA we deemed specific to the specialty market. In addition, there were eight supplemental drug approvals. The FDA had assigned eight new products for review and assigned five potential specialty products with June 2018 PDUFA dates. […]

New Drug Overview: Epoetin alfa-epbx (Retacrit®) Generic Name Brand Name Manufacturer Approval Date Anticipated Availability Accelerated Review Epoetin alfa-epbx Retacrit® Hospira Inc., a Pfizer company May 15, 2018 Not available n/a Labeled Indications: For the treatment of anemia caused by Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis For the treatment […]

Day 2 AMCP 2018 presentations provided continuing opportunities for learning, networking and the sharing of ideas. Today’s headline session presented by Douglas Long, BS, MBA focused on pharmacy marketplace trends.  Of note was that Hepatitis is no longer a key topic, demonstrating a trend towards successful treatment of this patient population.  While the data presented […]

RJHS – Drug Alert FDA Drug Approval – Ibalizumab-uiyk (TrogarzoTM) On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved a first in class treatment for adults with multi-drug resistant (MDR) HIV-1 infection, with a manufacturer’s initial estimated annual treatment cost of $118,000. An initial overview is listed below.  For additional Information on […]